Journal article
Outcomes of synchronous systemic and central nervous system (CNS) involvement of diffuse large B-cell lymphoma are dictated by the CNS disease: a collaborative study of the Australasian Lymphoma Alliance
JC Wight, M Yue, C Keane, A Johnston, K Linton, C Chin, SH Wai, D Talaulikar, R Gasiorowski, CY Cheah, GP Gregory, M Dickinson, A Minson, C Coombes, M Ku, S Lam, EA Hawkes
British Journal of Haematology | WILEY | Published : 2019
DOI: 10.1111/bjh.16064
Abstract
De novo diffuse large B-cell lymphoma (DLBCL) presenting with synchronous central nervous system (CNS) and systemic disease (synDLBCL) is not well described and is excluded from clinical trials. We performed a retrospective analysis of 80 synDLBCL patients treated across 10 Australian and UK centres. Of these patients, 96% had extranodal systemic disease. CNS-directed treatment with combination intravenous cytarabine and high-dose methotrexate (“CNS-intensive”) (n = 38) was associated with favourable survival outcomes compared with “CNS-conservative” strategies such as intravenous high-dose methotrexate monotherapy, intrathecal therapy and/or radiotherapy (2-year progression-free survival [P..
View full abstract